The direct or indirect effects of IL-6, IL-8, IL-10, TGF-β, C-C motif chemokine ligand 2 (CCL2), C-X-C motif chemokine ligand 9 (CXCL9), and CXCL10, but not limited to those, on tumor immunity in patients with oral, breast, and pancreatic cancer have been investigated [102–104]. The gene discussed is CXCL9; the disease is neoplasm.